Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Blood (2019) 134 (Supplement_1): 4015.

https://doi.org/10.1182/blood-2019-127199

Published: 2019

Journal Articles

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

Blood (2014) 124 (21): 76.

https://doi.org/10.1182/blood.V124.21.76.76

Published: 2014

Journal Articles

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Anna Skowronska, Gulshanara Ahmed, Ceri E Oldreive, PhD, David Oscier, MD, Anton Parker, Martin J.S. Dyer, MA, DPhil, Estella Matutes, MD, PhD, A. Malcolm R Taylor, PhD, Paul AH Moss, MD PhD, Tatjana Stankovic, MD PhD

Blood (2011) 118 (21): 467.

https://doi.org/10.1182/blood.V118.21.467.467

Published: 2011

Journal Articles

Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL)

Andrew Hodson, MD, Silvia Montoto, MD, Naheed Mir, MD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Kate Cwynarski, MD, PhD, Kirit M Ardeshna, MD, Thurai Kumaran, MD, Estella Matutes, MD, PhD, Graham Talyor, MD, Paul Fields, MD, PhD

Blood (2010) 116 (21): 3961.

https://doi.org/10.1182/blood.V116.21.3961.3961

Published: 2010

Journal Articles

Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia.

Sarah L Hockley, PhD, Alison Morilla, Andrew Wotherspoon, MD, PhD, Brian A Walker, PhD, Nicholas J Dickens, PhD, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD, Estella Matutes, MD, PhD, David Gonzalez, PhD

Blood (2009) 114 (22): 3467.

https://doi.org/10.1182/blood.V114.22.3467.3467

Published: 2009

Journal Articles

Increased Frequency of Constitutional Pathogenic ATM Mutations in CLL Patients Compared to Control Individuals Suggests An Aetiological Role.

Tatjana Stankovic, MD.PhD, Belinda Austen, Guy Pratt, Anna Skowronska, David Oscier, Martin JS Dyer, Estella Matutes, MD, PhD, Malcolm Taylor, Paul Moss, MBBS, PhD, FRCP

Blood (2009) 114 (22): 1250.

https://doi.org/10.1182/blood.V114.22.1250.1250

Published: 2009

Journal Articles

European Leukemianet (ELN) Project Diagnostic Platform (WP10): Final Results of the First Study of the European Morphology Consensus Panel.

Blood (2008) 112 (11): 1645.

https://doi.org/10.1182/blood.V112.11.1645.1645

Published: 2008

Journal Articles

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant

Sarah L Hockley, PhD, Monica Else, MA, MSc, Paola E Leone, PhD, Brian A Walker, Alison Morilla, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD, Estella Matutes, MD, PhD, David Gonzalez, PhD

Blood (2008) 112 (11): 3136.

https://doi.org/10.1182/blood.V112.11.3136.3136

Published: 2008

Journal Articles

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Sarah L Hockley, PhD, David Gonzalez, PhD, Vasantha Brito-Babapulle, PhD, Monica Else, MA, MSc, Paola E Leone, Brian A Walker, Estella Matutes, MD, PhD, Claire E Dearden, MD, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 3140.

https://doi.org/10.1182/blood.V112.11.3140.3140

Published: 2008

Journal Articles

Alemtuzumab Administered by Subcutaneous Route Is Less Effective Than Intravenous Route for First Line Therapy of T-Cell Prolymphocytic Leukaemia: Results of a Pilot Study (UKCLL05)

Ami t S Khot, Estella Matutes, MD, PhD, Pawel A Kaczmarek, Mike Hamblin, Ashok Roy, Effie Grand, Mark E Ethell, Claire E Dearden, MD

Blood (2008) 112 (11): 4204.

https://doi.org/10.1182/blood.V112.11.4204.4204

Published: 2008

Journal Articles

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Monica Else, MA, MSc, Claire E. Dearden, MD, Estella Matutes, MD, Ama Z S Rohatiner, MD, Steve A N Johnson, MD, Nigel T J O’Connor, MD, Andy Haynes, MD, Nnenna Osuji, MD, Daniel Catovsky, MD, DSc(Med)

Blood (2008) 112 (11): 2101.

https://doi.org/10.1182/blood.V112.11.2101.2101

Published: 2008

Journal Articles

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion

David Gonzalez, PhD, Pilar Martinez, MD, PhD, Rachel Wade, Sarah Lorna Hockley, PhD, Vasantha Brito-Babapulle, PhD, David Graham Oscier, MD, Estella Matutes, MD, PhD, Claire E Dearden, Sue Richards, Daniel Catovsky, MD, Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 784.

https://doi.org/10.1182/blood.V112.11.784.784

Published: 2008

Journal Articles

Different IGH Rearrangement and Somatic Hypermutation Patterns in Hairy-Cell Leukemia, Hairy-Cell Leukemia Variant and Splenic Marginal Zone Lymphoma.

Sarah L. Hockley, PhD, Stavroula Giannouli, MD, Alison Morilla, BSc, Gareth J. Morgan, MD, PhD, Estella Matutes, MD, PhD, David Gonzalez, PhD

Blood (2007) 110 (11): 2082.

https://doi.org/10.1182/blood.V110.11.2082.2082

Published: 2007

Journal Articles

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Hazem A. Sayala, MD, Paul Moreton, MD, Richard A. Jones, PhD, Andy C. Rawstron, PhD, Sheila J. O’Connor, PhD, Paul Evans, PhD, Carter Anthony, MsC, Claire Dearden, MD, Estella Matutes, MD, PhD, Andrew R. Pettitt, MD, PhD, Daniel B. Kennedy, MD, Peter Hillmen, MD, PhD

Blood (2006) 108 (11): 34.

https://doi.org/10.1182/blood.V108.11.34.34

Published: 2006

Journal Articles

Prognostic Factors in the UK LRF CLL4 Trial.

David Graham Oscier, MD, Rachel Wade, MSc, Jenny Orchard, MD, Zadie Davis, MSc, Giles Best, PhD, Alison Morilla, BSc, Vasantha Brito-Bapapulle, PhD, Estella Matutes, MD, Sue Richards, DPhil, Daniel Catovsky, MD

Blood (2006) 108 (11): 299.

https://doi.org/10.1182/blood.V108.11.299.299

Published: 2006

Journal Articles

VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information.

David Graham Oscier, MD, Zadie Davis, MSc, Patricia Algara, MD, Alexandra Traverse-Glehen, MD, Kostos Stamatopoulos, MD, Jan Delabie, MD, Anne Gardiner, BSc, Chrysoula Belessi, MD, Nikolaos Loutaris, MD, Estella Matutes, MD, Gilles Salles, MD, Manuela Mollejo, MD, Miguel Piris, MD

Blood (2006) 108 (11): 2421.

https://doi.org/10.1182/blood.V108.11.2421.2421

Published: 2006

Journal Articles

Combined aCGH and Mutational Analysis of CLL Patients with 17p Deletion.

Hannah C. Rudenko, MSc, Vasantha Brito-Babapulle, PhD, David Gonzalez, PhD, Pilar Martinez, MD, Paola E. Leone, PhD, Chris Jones, PhD, Tim Dexter, PhD, Kerry Fenwick, MSc, Alan Mackay, BSc, Alan Ashworth, PhD, Estella Matutes, MD, Daniel Catovsky, MD, Claire Dearden, MD, Gareth J. Morgan, MD,PhD

Blood (2006) 108 (11): 2091.

https://doi.org/10.1182/blood.V108.11.2091.2091

Published: 2006

Journal Articles

Comparison of IgH Gene Rearrangement Configuration between Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia Variant (HCL-v).

David Gonzalez, PhD, Ricardo Morilla, MSc, Alison Morilla, BSc, Monica Else, MSc, Nnenna Osuji, MD, Daniel Catovsky, MD, Claire Dearden, MD, Gareth J. Morgan, MD, PhD, Estella Matutes, MD

Blood (2005) 106 (11): 4997.

https://doi.org/10.1182/blood.V106.11.4997.4997

Published: 2005

Journal Articles

B- Cell Chronic Lymphocytic Leukaemia Complicated by Aggressive T-Cell Lymphoma: Clinical and Molecular Analysis of a Rare Variant of Richter’s Syndrome.

Ferdinandos Skoulidis, MRCP, Kevin Boyd, MRCP, David Cunningham, MD, FRCP, Andrew Wotherspoon, MRCPath, David Gonzalez, PhD, Daniel Catovsky, MD, FRCP, FRCPath, Gareth Morgan, FRCP, PhD, FRCPath, Estella Matutes, MD, PhD, Claire Dearden, MD, FRCP, MRCPath

Blood (2005) 106 (11): 4999.

https://doi.org/10.1182/blood.V106.11.4999.4999

Published: 2005

Journal Articles

Combinations of ZAP-70, CD38 and IgVH Mutational Status as Predictors of Time to First Treatment in CLL.

Alison Morilla, BSc, David Gonzalez, PhD, Ilaria Del Giudice, MD, Ricardo Morilla, MSc, Estella Matutes, MD, Claire Dearden, MD, Daniel Catovsky, MD, Gareth Morgan, PhD

Blood (2005) 106 (11): 711.

https://doi.org/10.1182/blood.V106.11.711.711

Published: 2005

NARROW

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL)

Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia.

Increased Frequency of Constitutional Pathogenic ATM Mutations in CLL Patients Compared to Control Individuals Suggests An Aetiological Role.

European Leukemianet (ELN) Project Diagnostic Platform (WP10): Final Results of the First Study of the European Morphology Consensus Panel.

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Alemtuzumab Administered by Subcutaneous Route Is Less Effective Than Intravenous Route for First Line Therapy of T-Cell Prolymphocytic Leukaemia: Results of a Pilot Study (UKCLL05)

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion

Different IGH Rearrangement and Somatic Hypermutation Patterns in Hairy-Cell Leukemia, Hairy-Cell Leukemia Variant and Splenic Marginal Zone Lymphoma.

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Prognostic Factors in the UK LRF CLL4 Trial.

VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information.

Combined aCGH and Mutational Analysis of CLL Patients with 17p Deletion.

Comparison of IgH Gene Rearrangement Configuration between Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia Variant (HCL-v).

B- Cell Chronic Lymphocytic Leukaemia Complicated by Aggressive T-Cell Lymphoma: Clinical and Molecular Analysis of a Rare Variant of Richter’s Syndrome.

Combinations of ZAP-70, CD38 and IgVH Mutational Status as Predictors of Time to First Treatment in CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only